HDR brachytherapy for prostate cancer that returned after prior radiation
Part of Cancer, Kidney & urinary clinical trials.
This trial studies a targeted, high-dose form of radiation (HDR brachytherapy) for prostate cancer that has come back after earlier radiation treatment. It aims to treat a limited (one-area) recurrence while trying to avoid serious late side effects from repeat radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 45 years old, and your doctor expects you to live at least 10 more years
- You had prior radiation to the prostate area (external-beam radiation or low-dose-rate brachytherapy)
- At least 3 years have passed since your prior radiation ended
- You did not have significant late side effects from the earlier radiation (no grade 2 or higher)
- Your PSA blood test is higher than its lowest point by at least 2 but less than 10
- Your scans show a single, limited place where the cancer has come back, with no spread to abdomen/pelvis or bones
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
This trial studies high-dose radiation (HDR) given after prostate cancer returns only in the prostate/seminal vesicles. It may help by trying to control the cancer when it has not spread elsewhere, using targeted treatment based on MRI and biopsy proof.
This trial tests a high-dose radiation treatment (brachytherapy) that places tiny radioactive seeds directly into the area where your prostate was. It is for men whose prostate cancer has returned only in that area after having their prostate removed.
This study tests a focused (“salvage”) brachytherapy—radiation placed directly near the prostate—to treat prostate cancer that has returned after earlier radiation. It may help control the tumor while limiting radiation exposure to surrounding tissues, based on how well people fit the study’s safety and cancer details.
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Hear when a new Recurrent Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.